FS-118 is a Monoclonal Antibody owned by F-star Therapeutics, and is involved in 3 clinical trials, which are ongoing.

FS-118 is a bi-specific monoclonal antibody acts by inhibiting programmed cell death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) and elicits anti-neoplastic activity. LAG-3 is an inhibitory receptor that regulate T-cell function to promote tumoral immune escape. It also functions at multiple levels to ensure appropriate T-cell homeostasis, activation, and differentiation. This protein binds with PD-L1 that is expressed in cancer cells and protects the cancer cells from immune system. The drug candidate targets both PD-L1 and LAG-3, promotes anti-tumor immunity and suppresses the tumorigenesis.

The revenue for FS-118 is expected to reach a total of $185m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the FS-118 NPV Report.

FS-118 was originated by F-star Biotechnology and is currently owned by F-star Therapeutics.

FS-118 Overview

FS-118 is under development for the treatment of metastatic solid tumor including head and neck cancer squamous cell carcinoma, non-small cell lung cancer (NSCLC) and diffuse large B cell lymphoma (DLBCL) . The drug candidate is a mAb-square immuno-regulatory monoclonal antibody administered intravenously. The therapeutic candidate consists of Fcab region in place of normal Fc region. It is a bi-specific antibody against two checkpoint inhibitors. The drug candidate acts by targeting programmed cell death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3).

F-star Therapeutics Overview

F-star Therapeutics, formerly Spring Bank Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company. It discovers and develops novel class of therapeutics. The company develops nucleotide-based drugs and small molecule nucleic acid hybrids. Its development pipeline products include FS118, FS120, FS222, SB 11285, among other drug candidates. The company’s drug products are used in the rescuing CPI treatment failures, improving outcomes in CPI naive, PD-L1 low tumors, chemotherapy outcomes, CPI outcomes, addressing unmet needs. Its partners programs include multiple blood brain barrier, multiple immuno-oncology, STING inhibitor, multiple next generation bispecifics. Spring Bank is headquartered in Hopkinton, Massachusetts, the US.

The company reported revenues of (US Dollars) US$21.2 million for the fiscal year ended December 2021 (FY2021), an increase of 88.1% over FY2020. The operating loss of the company was US$30.7 million in FY2021, compared to an operating loss of US$22.4 million in FY2020. The net loss of the company was US$31.3 million in FY2021, compared to a net loss of US$25.6 million in FY2020.

Quick View – FS-118

Report Segments
  • Innovator
Drug Name
  • FS-118
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.